Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 7/20 | 0.56 |
| ▸ | F2 | P00734 | 2/20 | 0.56 |
| ▸ | PLAT | P00750 | 1/20 | 0.56 |
| ▸ | KLK1 | P06870 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.42 |
| ▸ | RHOC | P08134 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | SIGLEC9 | Q9Y336 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8358929 | 0.93 | F10 (0.55) | F10F2PLATKLK1SYK | |
| SCHEMBL13900088 | 0.92 | F10 (0.55) | F10F2PLATKLK1SYK | |
| SCHEMBL13900057 | 0.85 | F10 (0.49) | F10F2PLATKLK1SYK | |
| SCHEMBL8358941 | 0.84 | F10 (0.55) | F10F2PLATKLK1SYK | |
| SCHEMBL8357171 | 0.83 | KDM4E (0.53) | DRD2DRD3 | |
| SCHEMBL8354665 | 0.83 | F10 (0.51) | F10F2PLATKLK1SYK | |
| SCHEMBL13900118 | 0.82 | F10 (0.67) | F10F2PLATKLK1RHOC | |
| SCHEMBL8357179 | 0.79 | F10 (0.66) | F10F2PLATKLK1MEN1 | |
| SCHEMBL1675028 | 0.79 | F10 (0.59) | F10F2PLATKLK1RHOC | |
| SCHEMBL8354993 | 0.79 | F10 (0.63) | F10F2PLATKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | F10 10/4885F2 3/4885PLAT 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.